Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | NR1D1 | P20393 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677156 | 1.00 | PTPN1 (0.51) | PTPN1NR1D1HDAC8P2RX7NPSR1 | |
| SCHEMBL32676714 | 1.00 | PTPN1 (0.51) | PTPN1NR1D1HDAC8P2RX7NPSR1 | |
| SCHEMBL29798976 | 1.00 | PTPN1 (0.51) | PTPN1NR1D1HDAC8P2RX7NPSR1 | |
| SCHEMBL32676857 | 0.95 | PTPN1 (0.46) | PTPN1NR1D1P2RX7NPSR1ACE | |
| SCHEMBL32677157 | 0.95 | PTPN1 (0.46) | PTPN1NR1D1P2RX7NPSR1ACE | |
| SCHEMBL31205615 | 0.90 | PTPN1 (0.51) | PTPN1HDAC8P2RX7NPSR1POLB | |
| SCHEMBL4459320 | 0.88 | PTPN1 (0.40) | PTPN1NR1D1HDAC8NPSR1POLB | |
| SCHEMBL8736850 | 0.88 | POLB (0.41) | PTPN1NR1D1HDAC8NPSR1POLB | |
| SCHEMBL32676675 | 0.88 | PTPN1 (0.53) | PTPN1NR1D1HDAC8NPSR1ACE | |
| SCHEMBL32677213 | 0.88 | PTPN1 (0.53) | PTPN1NR1D1HDAC8NPSR1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| CN-106008569-B9 | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-106008569-B | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-04-03 | — | — | CN | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3034509-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2632927-B1 | BORONATES AS ARGINASE INHIBITORS | MARS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| EP-2632927-A1 | BORONATES AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | PTPN1 2334/4885NR1D1 87/4885HDAC8 1057/4885 |
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | PTPN1 2334/4885NR1D1 87/4885HDAC8 1057/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PTPN1 2334/4885NR1D1 87/4885HDAC8 1057/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | PTPN1 2334/4885NR1D1 87/4885HDAC8 1057/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | PTPN1 2334/4885NR1D1 87/4885HDAC8 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.